← All trials
NCT07218809
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 28, 2025
- Primary completion
- Nov 17, 2028
- Completion date
- May 27, 2030
- First posted
- Oct 20, 2025
- Last posted
- Oct 20, 2025
- Enrollment
- 1100
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AstraZenecaLead sponsor
- GOG Foundation, Inc.Collaborator
- European Network for Gynaecological Oncological TrialCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.